No connection

Search Results

RNXT vs ZYBT

RNXT
RenovoRx, Inc.
BEARISH
Price
$1.00
Market Cap
$45.1M
Sector
Healthcare
AI Confidence
85%
ZYBT
Zhengye Biotechnology Holding Limited
BEARISH
Price
$0.92
Market Cap
$43.6M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
RNXT
--
ZYBT
--
Forward P/E
RNXT
-8.33
ZYBT
--
P/B Ratio
RNXT
6.76
ZYBT
1.01
P/S Ratio
RNXT
40.12
ZYBT
0.28
EV/EBITDA
RNXT
-3.19
ZYBT
-66.84

Profitability

Gross Margin
RNXT
70.88%
ZYBT
37.37%
Operating Margin
RNXT
-1269.75%
ZYBT
-46.33%
Profit Margin
RNXT
0.0%
ZYBT
-12.6%
ROE
RNXT
-225.62%
ZYBT
-6.38%
ROA
RNXT
-92.59%
ZYBT
-3.45%

Growth

Revenue Growth
RNXT
453.5%
ZYBT
-34.4%
Earnings Growth
RNXT
--
ZYBT
--

Financial Health

Debt/Equity
RNXT
0.04
ZYBT
0.23
Current Ratio
RNXT
4.02
ZYBT
1.49
Quick Ratio
RNXT
3.65
ZYBT
1.0

Dividends

Dividend Yield
RNXT
--
ZYBT
--
Payout Ratio
RNXT
0.0%
ZYBT
0.0%

AI Verdict

RNXT BEARISH

RNXT exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress and poor operational efficiency. While the company maintains a strong liquidity position with a current ratio of 4.02 and very low debt, it is burning cash at an unsustainable rate with an operating margin of -1269.75%. The valuation is disconnected from fundamentals, trading at a Price/Sales ratio of 40.12. Despite aggressive 'strong buy' analyst targets of $6.88, the deterministic data suggests a high-risk speculative profile with a long-term bearish price trend.

Strengths
Strong short-term liquidity (Current Ratio: 4.02)
Very low leverage (Debt/Equity: 0.04)
Explosive year-over-year revenue growth (453.50%)
Risks
Extreme operational inefficiency (Operating Margin: -1269.75%)
Severe fundamental health failure (Piotroski F-Score: 1/9)
Extreme valuation premium (Price/Sales: 40.12)
ZYBT BEARISH

ZYBT presents a high-risk profile characterized by a catastrophic price collapse and severe revenue contraction. While the Piotroski F-Score of 5/9 suggests stable internal financial health and the low Debt/Equity ratio (0.23) indicates minimal leverage, these are overshadowed by a -34.40% YoY revenue decline and negative operating margins. The stock is currently trading near its 52-week low after a massive 88.2% one-year decline, signaling a complete loss of investor confidence. Despite a low Price/Sales ratio of 0.28, the lack of growth and profitability makes the current valuation a value trap.

Strengths
Stable Piotroski F-Score (5/9)
Low Debt/Equity ratio (0.23)
Healthy Current Ratio (1.49)
Risks
Severe revenue contraction (-34.40% YoY)
Deeply negative operating margins (-46.33%)
Catastrophic price performance (-88.2% 1Y)

Compare Another Pair

RNXT vs ZYBT: Head-to-Head Comparison

This page compares RenovoRx, Inc. (RNXT) and Zhengye Biotechnology Holding Limited (ZYBT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile